Index

absolute product protection see product protection
abstract ideas 3, 131, 146–51, 195–8
abuse see market power abuse
Aerotel Ltd v Teico Holdings 61, 64
Affymetrix 279
Agreement on Trade Related Aspects of Intellectual Property Rights see TRIPS
AGREVO/Triazoles case 58
agriculture 65, 135, 291
agrochemicals 94–6
algorithms 27, 147–8
Allison, John 13–14
Amazon case 58, 87, 170
AMD 120
American Civil Liberties Union (ACLU) 4, 264–7, 270, 272–3, 278, 280–86
American Cyanamid Co (Dann’s) Patent 88
Amgen case
Amgen v. Chugai Pharm. Co. 272, 282–3, 287
Kirin-Amgen Inc v Hoescht Marion Roussel Ltd 57–9, 89, 283
Kirin-Amgen Inc. v. Transkarvotic Therapies Inc. 289, 296–7
amino acids 269–70, 272, 290
animal testing 235, 313, 315, 317–18
anticommons 21–3, 28–31, 137, 274
antitrust law 2, 126, 186, 195
Arora, Ashish 15
Arrow, Ken 18–19
Asahi Kasei Kogyo KK 289
Association for Molecular Pathology 264
Astra Zeneca v Commission 108, 112–13, 115, 121, 127
Australian High Court 66
Barker, Alyson 206
BDPI Phosphatase/Max-Planck case 291
Benkler, Yochai 336
Berne Convention 158
Bessen, James 135
BGH see German Federal Court
Bilski v Kappos 3, 193–218
Biogen Inc v Medeva plc 58, 88, 297
biological material 251, 253, 255
morality 236
scope of patents 222, 245–6, 249
excluded subject matter 298
invention requirement 80–83
morality 313
stem cell patentability 4
Blackberry 204
blastocyst 223, 241–3, 289, 319–20
blocking patents 21
BRCA 1 & 2 genes see breast cancer genes
breast cancer genes 4, 87, 263–5, 270–73, 277–87
Breyer, Justice 195–7
British Airways v Commission 123–4
British Technology Group 72
Brüstle case 240–43
Bundesgerichtshof (BGH) see German Federal Court
bundling 109, 114
Burk, Dan 216
business methods 145–51
Bilski case 193–7, 216–17
industry-specific patents 33, 35
invention categorization 87–8
patentability 2–3
protection exclusion 25–6, 59–61, 74, 163
US patents 143
CAD/CAM 134
Canada 211
Canadian patent law 296
cancer 87, 315
see also breast cancer genes; ovarian cancer
CFPH 60
chemical 65, 73
analog 25, 29
compound 98, 229, 316
industry 36, 172
patents 14
products 73
utility 65
Christian Franceries 74, 88
Classen Immunotherapies Inc v Biogen Idec 198, 201
clinical trials 93–4, 97, 281
cloning
human beings 235, 313, 332
software 125
Code of Industrial Property Rights, Italy 92
competition law 2, 43, 104–28, 138
competitive innovation 25–6
Computer Software Copyright Act 158
copyright protection 105–16, 187, 191
open source 177
SMEs 174
software 86, 154–8
Council of Europe 75, 82
Committee of Experts on Patents 78
Court of Justice of the European Union (CJEU) see European Court of Justice (ECJ)
cross-licensing 23, 31, 54
see also license
cumulative innovation 19–21, 25–8
damages 202–7, 212–14, 276–7, 280
database protection 106, 187, 189
debugging 11
design rights 111
diagnostic testing 4, 264–5, 273, 281–2, 285–6
Diamond v Chakrabarty 3, 260–61, 267, 335
disclosure 140, 297
biotechnology patents 34
gene patenting 273
Kirin-Amgen case 89
PHOSITA 37
stem cells 293–5
DNA 22
cancer genes 265
microarrays 269, 279
related invention 225–9, 234, 251
testing time 29
DNA sequence 272–3, 286, 291
anticommons 22
Biotech Directive 83
isolation 4
Monsanto case 247–58
patent scope 34
patentability 223–33
PTO Guidelines 263
see also gene sequencing
dominance 105, 108–25, 128
erBay Inc v MercExchange LLC 197, 204–5, 280
economic analysis 172
Edinburgh case 322, 324, 332
Eli Lilly v Human Genome Sciences Inc 81, 227, 290, 295, 308
embryo see human embryo
embryoid bodies 240
Enlarged Board of Appeal of the European Patent Office 3
embryo definition 302–7
human embryos 241–3
invention requirement 291
software patentability 86, 131, 166
stem cell patentability 237–9
Symbian case 61–2
WARF patent 323
EPC see European Patent Convention
Epogen 282
EPSPS enzyme 247
erthropoietin 282–3
European Commission abuse 126
Index

Astra Zeneca case 121
Directive (87/54) 189
Directive (91/250) 125, 127
intellectual property 127
intellectual property rights 112–16
Lisbon Treaty 325
Microsoft case 120, 122, 124–5
Nice Charter 325
Regulation on Community Designs 190
European Commission Biotech Directive see Biotech Directive
European Council of Ministers Competitiveness Council 161
European Court of First Instance (CFI) 112
European Court of Human Rights 326, 334
European Court of Justice (ECJ) 72, 229
Biotech Directive 249
competition 122
monopoly 116
morality 325–6, 331, 333
stem cells 240–41
see also Court of Justice of the European Union (CJEU)
European General Court 112, 115, 122–3, 126
European Patent Convention 1–2, 299–302, 305, 312–19
computer program exclusion 86, 164
ethics 309
exclusions from patentable subject matter 56, 59–71, 74–6, 84–6, 157–9
Implementing Regulations 4, 69, 76, 313
industrial application requirement 225, 227–8, 291–3
insufficient disclosure 296
invention requirement 55–8, 62–76, 85, 87, 169–70
product patents 245
software patentability 146, 161–3
stem cell patents 234–9
European Patent Office 297–305
Biotech Directive conflict 234–5
Biotech Directive provisions 257
breast cancer (BRCA) susceptibility genes 263
disclosure 297
gene patenting 223
human embryo 243
industrial application requirement 227
invention requirement 59–63, 72, 74, 77, 80–83, 87, 89
jurisprudence 4, 71
legal uncertainty 159
morality 308, 316, 331, 333
Opposition Division 316–18
software definition 144–5
software patentability 58, 63, 171
software patents granted 156
stem cell patent refusal 322
stem cell patents 237
Technical Board of Appeal see Technical Board of Appeal
Euthanasia Compositions case 316
extraterritorial patent infringement 208–9
Exxon case 62, 82–3, 89
Fair, Reasonable and Non-Discriminatory Terms (FRAND) 105, 108–9
Federal Circuit see United States Court of Appeal of the Federal Circuit (CAFC)
Federal Trade Commission (FTC) 262–4, 283–4
first-to-invent priority system 194, 217
Food and Drug Administration (FDA) 24, 96–7, 283, 285
fragmentation 89, 136–7, 140, 310, 314
free software 175, 178–9
see also open source
Freeman Walter Abele test 148
Fujitsu Ltd case 59, 63
G_003/8 case, President Reference/Computer Program Exclusion, decision by the Enlarged Board of Appeal of the EPO 56, 131, 145–6, 166–7
GenBank 273
gene fragment 29, 269, 272–3, 279–80
gene patenting 4, 260–87

Emanuela Arezzo and Gustavo Ghidini - 9780857938039
Downloaded from Elgar Online at 06/15/2019 09:52:43AM
via free access
gene sequencing 4, 29, 249, 265, 267
generic drugs 127, 283
manufacturers 24, 29, 33
market dominance 105, 108, 121
patent expiry 93–6
Generics v Lundbeck 56, 85
genetically modified 232, 244, 247, 249, 260, 314–18
genome
  artificial 289, 295, 307
  human 267, 275, 285
Genomic Research and Diagnostic Accessibility Act 284
Georgia-Pacific Corp. v United States Plywood Corp 214
German Federal Court 167–8, 240–42
German law 149
German Patent Act 142
Germany 75, 228–9, 240
Ghosh, Professor Shubha 202
Ginsburg, Justice 195–6
H2 blockers 113
Haase, Heiko 133
Hague Court 247–9
Halliburton Energy Services Inc v Smith International Inc 59–60, 64
Heller, Michael 21
Hematopoietic cytokine receptor/Zygmogenetics 292
hemoglobin 269–70
heterogeneity 10, 13–15
HGS see Eli Lilly v Human Genome Sciences Inc
Hoffman, Lord 59, 61–3, 88, 197
horticulture 65
House of Lords see United Kingdom, House of Lords
human embryo 241–5, 289–327
  patent exclusion 4, 222, 235–43
human embryonic stem cells (hESC)
  morality 315
  patentability 4
  pluripotent 321
human genome see genome, human

IBM 125
IBM/Computer Program Product I 164, 171
IBM/Computer Program Product II 164
IMS Health GmbH & Co v NDC Health GmbH & Co 112, 124
In re Bilski 71, 149, 194, 198, 199
incremental improvement 27–8, 40
industrial application 290–95, 307–8
  gene patenting 223–9
  invention requirement 71–6, 234, 298
  software patentability 161
industry-specific legislation 33–9
  absolute product protection 254
  business methods 195–6
  computer programs 86
  experimental exemption 103
  gene patenting 262–4, 271–80
  genetic testing 284–5
  insufficiency 296
  Microsoft case 108
  Monsanto case 247–9
  morality 317
  software patentability 176
  injunction 197, 203–6, 276, 280
  biotechnology 262–4, 310
  cumulative see cumulative innovation
  damages 212
  intellectual property 107–9
  Microsoft case 124–6
  sequential 135
  software patentability 152
  strategic patenting 140
Intel case 108, 120
intellectual property 12, 15–20, 28, 31–2, 330
  law 153, 210, 336
  protection 329
  see also TRIPS intellectual property rights (IPR)
  104–21
  morality 309, 311, 328, 335
  patent value 182
  product protection 127–8
  software patentability 31
  interface 150–51
International Patent Classification (IPC) 133
interoperability 27, 117, 124–5, 137–40
invention
  definition 82
  requirement 2, 55–90
IVF treatment 303
Jacob, Lord Justice 61
Jensen, Kyle 267–70
Joint Electron Device Engineering Council (JEDEC) 113, 116
Kennedy, Justice 195–6
Kirin-Amgen Inc v Hoescht Marion Roussel Ltd see Amgen
Kitch, Edmund 16–17
Kitchin, Justice 293
Kokott, Advocate General 123
KSR International Co v Telesflex Inc 197, 215–16
La Jolla Cancer Research Foundation 278
Laddie, Justice 59, 63
Landes, William 20
Leahy, Senator Patrick 209, 214, 217
Lear Corporation 211
Leland case 318
Lemley, Mark 13–14, 19, 216
license 15, 30, 48, 108, 120, 187
  agreements 51
    compulsory 105, 107, 119, 124, 127, 185–6
    fees 275
    manufacturing 118
    non-discriminatory 47
    non-voluntary 186
    open-source 51
    royalties 276
    sub-licenses 47, 49, 51
    system 50
    technology transfer 111–12
    voluntary 51, 212
  see also cross-licensing
Ligand Pharmaceuticals 278
Lisbon Treaty 325
Long, Clarissa 216
Losec 113, 115
Lourie, Judge 200–201
Lucent Technologies Inc v Gateway Inc 213–14
Luxembourg Convention on the Community Patent (CPC) 91–2
Machlup, Fritz 135, 191
Madey v Duke University 97
Magill case 116, 124
market power abuse 105, 107, 109–13, 116–27
  see also dominance
market power acquisition 117–18, 121
market share 114–16
Marshall, Texas 210
Maskin, Eric 135
Merges, Robert 19–20, 216
Merrell Dow Pharmaceuticals v HB Norton & Co Ltd 59, 61, 63
metabolites 199–201
micro-organisms 88, 260
microarray 269, 279–80
microprocessor 11, 31
  see also semiconductor industry
Microsoft 117
  Money 213–14
  Outlook 213–14
  Windows 114, 122, 213
  Windows Mobile 213–14
Microsoft Corp v AT&T Corp 208–9
Microsoft Corp v Commission 108, 112–16, 120, 122, 124
Mobil 72
monopoly 17–19, 89, 115–19, 293
  anticommmons 22
  Bilski v. Kappos case 196
  competitive innovation 25
  invention requirement 62
  stem cell patents 297–8
  see also dominance; market power abuse
Monsanto Technology LLC v Cefetra BV et al. 73, 83, 229–30, 234, 247–56, 258
Moore, Kimberly 14
morality 4, 235–6, 288, 298–337
  Biotech Directive 222
  European Union 242
  exclusion 76
  patent exclusion 258
Morse, Samuel 150–51
Munich 1973 Conference 73–4
Munich 2000 Conference 159
Murray, Fiona 267–70
Myriad Genetics 4, 264–6, 277–8, 280–81, 283–4, 286–7
Nard, Craig 216
National Research Development Corp v Commissioner of Patents 66, 69
Nelson, Richard 19–20
Netherlands case 324
Neuberger, Lord 61
neural precursor cells 240
Neutrokine-a 290
Nice Charter 325
NIH 224
No-Fume Ltd v Frank Pitchford & Co Ltd 296
NTP Inc v Research in Motion Ltd 204
nucleotide 272, 290
objective justification 110, 119, 124–6
oligonucleotide 279
Oncomouse decision 4, 314, 316–18
open source
community 160, 173, 175
model 51, 187
movement 43
software 175–9
operating system 117, 134, 138
ordre public 76, 235–42, 258, 299, 311–17, 325–6
ovarian cancer 87, 264–5
overlapping patents 23, 28, 30–31
Paris Convention 73, 80
Patent Cooperation Treaty (PCT) 67
patent examiners 178, 180, 183
patent overlap see overlapping patents
patent pool 45
patent theory 15–17, 23–4, 32
patent thickets 23, 30–32, 181, 276–7
flooding 109
gene patenting 274, 279
Penrose, Edith E.T. 135
pharmaceutical industry 29–33, 283
gene patenting 262
market dominance 105
product patents 14
research and development 11, 24–5
strategic patenting 108
PHOSITA 37–8
Plant Genetic Systems 316
patent plants 221, 244–6
plasmid 246
policy levers 10, 32, 37–9
polynucleotide probes 265–6
polypeptide 272, 292
pooling patents see patent pool
technique
Posner, Richard 20
Prescott, Peter, QC 60–61, 74
pricing policy 115
primary product markets 108, 111–12, 115–17
product protection 250
absolute 225–34, 250–51, 254–5, 258
purpose-bound 83, 224–9, 233–4
programmer 11, 88, 170, 173–8, 183
Prometheus Laboratories Inc v Mayo Collaborative Services 199–201
prospect theory 16–21, 24–5, 29
protein 272–3, 291
coding 248
DNA sequence 29
erthropoietin 282
production 227, 246
synthetic 270, 289
proton pump inhibitor (PPI) 112–13, 115, 121
PTO see United States Patent and Trademark Office
Pumfrey, Justice 60–61, 64, 74
purpose-bound product protection see product protection
Quanta Computer Inc v LG Electronics Inc 197
Rambus case 113, 115–16, 120
Read Corp v Portec Inc 206
recombinant cell 272–3
recombinant erythropoietin 282
Relaxin case 316
research and development 11, 24–6, 117, 329, 331
research exemption 91–104
Romer, Lord Justice 296
<table>
<thead>
<tr>
<th>Index</th>
<th>345</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rookridge, Bill 206, 216</td>
<td>supplementary protection certificate (SPC) 112, 127</td>
</tr>
<tr>
<td>Roundup-Ready (RR) soya 247</td>
<td>Switzerland 135</td>
</tr>
<tr>
<td>royalties 108–9, 118, 212, 270, 276–80, 332</td>
<td><em>Symbian v Comptroller General of Patents</em> 61–2, 81</td>
</tr>
<tr>
<td><em>eBay</em> case 204</td>
<td>synthetic biology 288–308</td>
</tr>
<tr>
<td>FRAND 113</td>
<td>Technical Board of Appeal <em>see</em> European Patent Office</td>
</tr>
<tr>
<td>patent pool 47</td>
<td>TFEU <em>see</em> Treaty on the Functioning of the European Union (TFEU)</td>
</tr>
<tr>
<td>reach-through licenses 30</td>
<td>Thomas, Justice 205</td>
</tr>
<tr>
<td>SACGHS Report 279, 281, 284</td>
<td>TRIPS 35, 80, 83–4, 142, 329–31</td>
</tr>
<tr>
<td>Scalia, Justice 195, 197</td>
<td><em>biotech patents</em> 311</td>
</tr>
<tr>
<td><em>Schlumberger Holdings Ltd v Electromagnetic Geoservices AS</em> 78</td>
<td>EBA declaration 239</td>
</tr>
<tr>
<td>Schumpeter, Joseph 17–19</td>
<td><em>Monsanto</em> case 250</td>
</tr>
<tr>
<td><em>Seagate</em> case 207–8</td>
<td>morality 334</td>
</tr>
<tr>
<td>secondary product markets 111–12, 117, 120</td>
<td>software 152, 158</td>
</tr>
<tr>
<td>Secretary’s Advisory Committee on Genetics, Health and Society (SACGHS) 280–81</td>
<td>stem cells 288, 306</td>
</tr>
<tr>
<td>Semiconductor Chip Protection Act (SCPA) 36</td>
<td><em>see also</em> intellectual property; intellectual property rights (IPR)</td>
</tr>
<tr>
<td>semiconductor industry 11–14, 32–3, 35–6, 113, 120, 189</td>
<td>trivial patents 140, 170, 178, 181, 184</td>
</tr>
<tr>
<td>patent thickets 23, 31</td>
<td><em>TS Tech USA Corp</em> case 211–12</td>
</tr>
<tr>
<td>Shapiro, Carl 23</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Sherman Act 117</td>
<td>Court of Appeal 61, 78, 81, 227, 296</td>
</tr>
<tr>
<td>SIEC 111</td>
<td>House of Lords 55, 62, 89, 289</td>
</tr>
<tr>
<td>SLC 111</td>
<td>law 145–6</td>
</tr>
<tr>
<td>small and medium-sized enterprises (SMEs) 173–6</td>
<td>United States Code Section (101) 199, 266</td>
</tr>
<tr>
<td>socio-economic analysis 161, 172</td>
<td>United States Congress 207–18, 264, 283–4, 334</td>
</tr>
<tr>
<td>software</td>
<td><em>Patent Reform Acts</em> 202–3</td>
</tr>
<tr>
<td>definition 132–4, 142–5</td>
<td>patent term length 33</td>
</tr>
<tr>
<td>patentability 134, 159–61, 171, 173, 188</td>
<td><em>United States Constitution</em> 141, 266, 335–7</td>
</tr>
<tr>
<td>software patents granted 156</td>
<td>United States Court of Appeal of the Federal Circuit (CAFC) 25, 203–11, 214–16, 265, 336</td>
</tr>
<tr>
<td>Sotomayer, Justice 195–6</td>
<td><em>business methods</em> 149, 194</td>
</tr>
<tr>
<td>soya 247–52</td>
<td><em>patent infringement</em> 94</td>
</tr>
<tr>
<td>standardization 12, 47, 113, 138</td>
<td><em>research exemption</em> 97</td>
</tr>
<tr>
<td><em>State Street Bank &amp; Trust Co. v Signature Financial Group</em> 196</td>
<td>United States legal system 334</td>
</tr>
<tr>
<td>stem cells <em>see</em> human embryonic stem cells (hESC)</td>
<td></td>
</tr>
</tbody>
</table>
Biotechnology and software patent law

United States Patent and Trademark Office 334–5
bacterium patentability 260
biotechnology patents 290
business methods 147
cancer gene patents 264–5
Congress 216–17
gene patent issuing 275
gene patenting 267
Guidelines 3–4, 198, 262–3
invention requirement 170
Manual of Patent Examination Procedure 148
patentability 194
software patentability 158
United States Supreme Court 193–218
Bilski case 3
business methods 149–51
Diamond v Chakrabarty 267
infringement damages 276
micro-organism patentability 260–61
research exemption 96
software patentability 131

University of Utah Research Foundation 265
university research 97, 99–100, 266, 275, 285
USPTO see United States Patent and Trademark Office

venue 202–3, 209–12
Vienna Convention on the Law of Treaties 64, 80
Volvo v Veng 111, 115, 120
Von Hellfeld, Axel 142

Walker, Lord 85
Weyand, Joachim 133
Whittemore v Cutter 91
willful infringement 203, 206–7, 277
Wisconsin Alumni Research Foundation (WARF) decision 4, 290, 301–2, 307–8, 322–4, 332

World Intellectual Property Organization (WIPO) 158, 188–9